<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="105963">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01999062</url>
  </required_header>
  <id_info>
    <org_study_id>UHN REB 12-5181-CE</org_study_id>
    <nct_id>NCT01999062</nct_id>
  </id_info>
  <brief_title>Automated Breast Radiation Therapy Using an MR-Guided Process</brief_title>
  <official_title>Automated Breast Radiation Therapy Using an MR-Guided Process</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Princess Margaret Hospital, Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <authority>Canada: Ethics Review Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the proposed research study, we are investigating the feasibility of integrating
      automated planning tools to MR images acquired using a novel MR-guided linac, for on-line
      adaptive radiation treatment. However, these on-line automation tools require further
      technical refinement and clinical validation. The goal of this research proposal is to
      develop an on-line MR-guided radiation therapy process for adapting breast IMRT treatment.
      Such an approach will provide early stage breast cancer patients timely access to
      high-quality adaptive treatments without exposure to additional ionizing radiation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Time between planning of Radiation treatment and the start of radiotherapy</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>The effect of breathing on the position of the heart and lung in treatment plans</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>IMRT + CT + MR scan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>IMRT + CT + MR scan</intervention_name>
    <arm_group_label>IMRT + CT + MR scan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who will receive standard two-field tangential whole breast radiation
             therapy with dose prescription of 4240 cGy in 16 fractions, 5000 cGy in 25 fractions
             or 4000 cGy in 16 fractions.

          -  Female patients with any stage of breast cancer.

          -  Patients with prior treatment such as surgery or chemotherapy for any type of cancer.

          -  Able to provide a written informed consent.

          -  â‰¥ 18 years of age.

        Exclusion Criteria:

          -  Patients who will not receive 4240 cGy in 16 fractions, 5000 cGy in 25 fractions, or
             4000 cGy in 16 fractions

          -  Males.

          -  Patients who received partial breast radiation and not the standard dose.

          -  Patients who are unable to provide informed consent.

          -  &lt; 18 years of age.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Dinniwell, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Princess Margaret Cancer Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tom Purdie, Physicist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Princess Margaret Cancer Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robert Dinniwell, M.D.</last_name>
    <phone>416-946-4501</phone>
    <phone_ext>4662</phone_ext>
    <email>rob.dinniwell@rmp.uhn.on.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tom Purdie, Physicist</last_name>
    <phone>416-946-4501</phone>
    <phone_ext>5074</phone_ext>
    <email>tom.purdie@rmp.uhn.on.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Dinniwell, M.D.</last_name>
      <phone>416-946-4501</phone>
      <phone_ext>4662</phone_ext>
      <email>rob.dinniwell@rmp.uhn.on.ca</email>
    </contact>
    <contact_backup>
      <last_name>Tom Purdie, PhD</last_name>
      <phone>416 946 4501</phone>
      <phone_ext>5074</phone_ext>
      <email>Tom.purdie@rmp.uhn.on.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Robert Dinniwell, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tom Purdie, Physicist</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 25, 2013</lastchanged_date>
  <firstreceived_date>June 11, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast RT</keyword>
  <keyword>Breast radiation therapy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
